Log in

Relevant bibliographies by topics / Antifibrotic Agents / Journal articles

To see the other types of publications on this topic, follow the link: Antifibrotic Agents.

Journal articles on the topic 'Antifibrotic Agents'

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antifibrotic Agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Albanis, E., and S. L. Friedman. "Antifibrotic Agents for Liver Disease." American Journal of Transplantation 6, no. 1 (2006): 12–19. http://dx.doi.org/10.1111/j.1600-6143.2005.01143.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

LaCamera, Peter P., Susan L. Limb, Tmirah Haselkorn, Elizabeth A. Morgenthien, John L. Stauffer, and Mark L. Wencel. "Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis." Chronic Respiratory Disease 16 (January 1, 2019): 147997311987967. http://dx.doi.org/10.1177/1479973119879678.

Full text

Abstract:

Pirfenidone and nintedanib are oral antifibrotic agents approved for the treatment of idiopathic pulmonary fibrosis (IPF). Real-world data on factors that influence IPF treatment decisions are limited. Physician characteristics associated with antifibrotic therapy initiation following an IPF diagnosis were examined in a sample of US pulmonologists. An online, self-administered survey was fielded to pulmonologists between April 10, 2017, and May 17, 2017. Pulmonologists were included if they spent >20% of their time in direct patient care and had ≥5 patients with IPF receiving antifibrotics.

APA, Harvard, Vancouver, ISO, and other styles

3

Skuta, Gregory L. "Antifibrotic Agents in Glaucoma Filtering Surgery." International Ophthalmology Clinics 33, no. 4 (1993): 165–82. http://dx.doi.org/10.1097/00004397-199303340-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Oishi, Keiji, Tsunahiko Hirano, Yoriyuki Murata, et al. "Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study." Therapeutic Advances in Respiratory Disease 13 (January 2019): 175346661987289. http://dx.doi.org/10.1177/1753466619872890.

Full text

Abstract:

Background: In patients with idiopathic pulmonary fibrosis (IPF), continuing treatment with antifibrotic agents is crucial to decrease the reduction of forced vital capacity and mortality rate. However, predictive factors for the discontinuation of antifibrotic agents are unknown. This study aims to investigate the clinical characteristics and predictive factors for the discontinuation of antifibrotic agents in patients with IPF. Methods: This was a double-center retrospective study that enrolled patients with IPF treated with pirfenidone or nintedanib between 2009 and 2017. We compared clinic

APA, Harvard, Vancouver, ISO, and other styles

5

Kawada, Norifumi. "Antifibrotic agents emerging from traditional herbal medicine." Arab Journal of Gastroenterology 10, no. 4 (2010): S21—S22. http://dx.doi.org/10.1016/j.ajg.2009.12.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Geismar, Lois S., Janet S. Kerr, Robert L. Trelstad, and David J. Riley. "Treatment of experimental silicosis with antifibrotic agents." Toxicology 53, no. 2-3 (1988): 331–44. http://dx.doi.org/10.1016/0300-483x(88)90225-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Grotendorst, Gary R. "Identification and development of novel antifibrotic agents." Expert Opinion on Investigational Drugs 6, no. 6 (1997): 777–81. http://dx.doi.org/10.1517/13543784.6.6.777.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Jegal, Yangjin, Jong Sun Park, Song Yee Kim, et al. "Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry." Tuberculosis and Respiratory Diseases 85, no. 2 (2022): 185–94. http://dx.doi.org/10.4046/trd.2021.0123.

Full text

Abstract:

Background: The Korea Interstitial Lung Disease Study Group has made a new nationwide idiopathic pulmonary fibrosis (IPF) registry because the routine clinical practice has changed due to new guidelines and newly developed antifibrotic agents in the recent decade. The aim of this study was to describe recent clinical characteristics of Korean IPF patients.Methods: Both newly diagnosed and following IPF patients diagnosed after the previous registry in 2008 were enrolled. Survival analysis was only conducted for patients diagnosed with IPF after 2016 because antifibrotic agents started to be co

APA, Harvard, Vancouver, ISO, and other styles

9

Schuppan, Detlef, Muhammad Ashfaq-Khan, Ai Ting Yang, and Yong Ook Kim. "Liver fibrosis: Direct antifibrotic agents and targeted therapies." Matrix Biology 68-69 (August 2018): 435–51. http://dx.doi.org/10.1016/j.matbio.2018.04.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Pan, Xiaoqi, Xiao Ma, Yinxiao Jiang, et al. "A Comprehensive Review of Natural Products against Liver Fibrosis: Flavonoids, Quinones, Lignans, Phenols, and Acids." Evidence-Based Complementary and Alternative Medicine 2020 (October 5, 2020): 1–19. http://dx.doi.org/10.1155/2020/7171498.

Full text

Abstract:

Liver fibrosis resulting from continuous long-term hepatic damage represents a heavy burden worldwide. Liver fibrosis is recognized as a complicated pathogenic mechanism with extracellular matrix (ECM) accumulation and hepatic stellate cell (HSC) activation. A series of drugs demonstrate significant antifibrotic activity in vitro and in vivo. No specific agents with ideally clinical efficacy for liver fibrosis treatment have been developed. In this review, we summarized the antifibrotic effects and molecular mechanisms of 29 kinds of common natural products. The mechanism of these compounds is

APA, Harvard, Vancouver, ISO, and other styles

11

Ismail, Magda M. F., and Eman Noaman. "Novel Pirfenidone Analogs as Antifibrotic Agents: Synthesis and Antifibrotic Evaluation of 2-Pyridones and Fused Pyridones." Medicinal Chemistry Research 14, no. 7 (2005): 382–403. http://dx.doi.org/10.1007/s00044-006-0146-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Slabaugh, Mark, and Sarwat Salim. "Use of Anti-VEGF Agents in Glaucoma Surgery." Journal of Ophthalmology 2017 (2017): 1–6. http://dx.doi.org/10.1155/2017/1645269.

Full text

Abstract:

A number of antivascular endothelial growth factor agents are currently available to treat various ocular conditions. These agents have similar, but distinct, biologic qualities and have been explored in the management of neovascular glaucoma and in glaucoma surgery. Several different delivery methods are described, and because these medications are routinely given as intraocular injections, some benefits over traditional antifibrotic medications when used in glaucoma surgery are noted. These agents effectively induce regression of anterior segment neovascularization and facilitate initial sur

APA, Harvard, Vancouver, ISO, and other styles

13

Fitzgerald, L. J., D. N. O'Dwyer, E. Wakeam, D. M. Lyu, and M. P. Combs. "Evaluation of Pre-Transplant Antifibrotic Agents on Post-Transplant Outcomes." Journal of Heart and Lung Transplantation 41, no. 4 (2022): S422—S423. http://dx.doi.org/10.1016/j.healun.2022.01.1064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Selman, Moisés. "From Anti-inflammatory Drugs Through Antifibrotic Agents to Lung Transplantation." Chest 122, no. 3 (2002): 759–61. http://dx.doi.org/10.1378/chest.122.3.759.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Mannem, Hannah, and Alexander Sasha Krupnick. "Commentary: Antifibrotic agents in the postoperative period: Friends or foes?" Journal of Thoracic and Cardiovascular Surgery 158, no. 1 (2019): 297–98. http://dx.doi.org/10.1016/j.jtcvs.2019.02.102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Takehara, Kazutaka, Yasuhiko Koga, Yoshimasa Hachisu, et al. "Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis." Cells 11, no. 1 (2022): 143. http://dx.doi.org/10.3390/cells11010143.

Full text

Abstract:

Antifibrotic agents have been widely used in patients with idiopathic pulmonary fibrosis (IPF). Long-term continuation of antifibrotic therapy is required for IPF treatment to prevent disease progression. However, antifibrotic treatment has considerable adverse events, and the continuation of treatment is uncertain in many cases. Therefore, we examined and compared the continuity of treatment between pirfenidone and nintedanib in patients with IPF. We retrospectively enrolled 261 consecutive IPF patients who received antifibrotic treatment from six core facilities in Gunma Prefecture from 2009

APA, Harvard, Vancouver, ISO, and other styles

17

Hassanein, Tarek, Dean Tai, Chenghai Liu, et al. "Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial." Evidence-Based Complementary and Alternative Medicine 2022 (July 15, 2022): 1–11. http://dx.doi.org/10.1155/2022/4494099.

Full text

Abstract:

Background. Hepatitis C virus (HCV) is a common cause of progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma worldwide. Despite the availability of effective direct-acting antivirals, patients often have significant hepatic fibrosis at the time of diagnosis due to delay in diagnosis and comorbidities which promote fibrogenesis. Thus, antifibrotic agents represent an attractive adjunctive therapy. Fuzheng Huayu (FZHY), a traditional Chinese medicine botanical formulation, has been used as an antifibrotic agent in chronic HBV infection. Our aim was to assess FZHY in patients wi

APA, Harvard, Vancouver, ISO, and other styles

18

Tanabe, Kiwamu, Tatsuya Usui, and Kazuaki Sasaki. "Search for novel antifibrotic agents using nonalcoholic steatohepatitis (NASH) organoid model." Proceedings for Annual Meeting of The Japanese Pharmacological Society 95 (2022): 1—LBS—04. http://dx.doi.org/10.1254/jpssuppl.95.0_1-lbs-04.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Rupcic Rubin, Vinka, Kristina Bojanic, Martina Smolic, Jurica Rubin, Ashraf Tabll, and Robert Smolic. "An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents." Journal of Clinical and Translational Hepatology 000, no. 000 (2021): 1–11. http://dx.doi.org/10.14218/jcth.2020.00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Ma, Zhen, Youlu Pan, Wenhai Huang, et al. "Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents." Bioorganic & Medicinal Chemistry Letters 24, no. 1 (2014): 220–23. http://dx.doi.org/10.1016/j.bmcl.2013.11.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Tang, X., S. Teng, M. Petri, C. Krettek, C. Liu, and M. Jagodzinski. "The effect of anti-inflammatory and antifibrotic agents on fibroblasts obtained from arthrofibrotic tissue." Bone & Joint Research 7, no. 3 (2018): 213–22. http://dx.doi.org/10.1302/2046-3758.73.bjr-2017-0219.r2.

Full text

Abstract:

Objectives The aims of this study were to determine whether the administration of anti-inflammatory and antifibrotic agents affect the proliferation, viability, and expression of markers involved in the fibrotic development of the fibroblasts obtained from arthrofibrotic tissue in vitro, and to evaluate the effect of the agents on arthrofibrosis prevention in vivo. Methods Dexamethasone, diclofenac, and decorin, in different concentrations, were employed to treat fibroblasts from arthrofibrotic tissue (AFib). Cell proliferation was measured by DNA quantitation, and viability was analyzed by Li

APA, Harvard, Vancouver, ISO, and other styles

22

Liang, Minrui, Eric L. Matteson, Andy Abril, and Jörg H. W. Distler. "The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease." Therapeutic Advances in Musculoskeletal Disease 14 (January 2022): 1759720X2210744. http://dx.doi.org/10.1177/1759720x221074457.

Full text

Abstract:

The major pulmonary complication of rheumatoid arthritis (RA) is interstitial lung disease (ILD), which causes significant morbidity and mortality and influences the natural course of disease. Recent advances in the management of arthritis have improved patient outcomes. However, exceptionally high medical needs still remain for effective therapies for the patients with ILD in RA. Better understanding of the shared and distinct pathophysiology of fibrotic diseases led to the development of novel antifibrotic agents such as nintedanib and pirfenidone. The further stratification analysis of the

APA, Harvard, Vancouver, ISO, and other styles

23

Corrie, Leander, MD Muzaffar-Ur-Rehman, Latha Kukatil, Devasari Manasa, and Adepu Shirisha. "Antifibrotic Drugs for COVID-19: From Orphan Drugs to Blockbusters?" Current Respiratory Medicine Reviews 17, no. 1 (2021): 8–12. http://dx.doi.org/10.2174/1573398x17666210304100043.

Full text

Abstract:

: Antifibrotic agents are known to treat idiopathic pulmonary fibrosis. The two antifibrotic agents approved and in usage are Pirfenidone and Nintedanib granted by the USFDA in 2014. They are both known to decrease inflammation in the lungs. The fact that COVID-19 has shown to cause inflammation and fibrosis in the lungs frames the theory of their usage in the treatment of the disease by reducing lung scaring and allowing faster discharge of patients with post-COVID complications. The need for them to change their status from orphans to blockbusters has not happened yet due to fewer data and l

APA, Harvard, Vancouver, ISO, and other styles

24

Koga, Yasuhiko, Yoshimasa Hachisu, Hiroaki Tsurumaki, et al. "Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels." Medicina 55, no. 5 (2019): 161. http://dx.doi.org/10.3390/medicina55050161.

Full text

Abstract:

Background: Antifibrotic agents have been approved for the treatment of idiopathic pulmonary fibrosis (IPF). However, the efficacy of these drugs in the treatment of familial IPF (FIPF) has not been previously reported. Case presentation: We report the case of a 77-year-old man with FIPF, successfully treated with pirfenidone. His uncle died due to IPF, and his niece was diagnosed with the disease. He had worsening dyspnea two months prior to admission to our hospital. Upon admission, he had desaturation when exercising and broad interstitial pneumonia. Administration of pirfenidone improved h

APA, Harvard, Vancouver, ISO, and other styles

25

Górska, Katarzyna, Marta Maskey-Warzęchowska, Małgorzata Barnaś, et al. "Therapeutic decisions in a cohort of patients with idiopathic pulmonary fibrosis: a multicenter, prospective survey from Poland." Therapeutic Advances in Chronic Disease 13 (January 2022): 204062232211179. http://dx.doi.org/10.1177/20406223221117982.

Full text

Abstract:

Background: Pirfenidone and nintedanib are considered as the standard of care in idiopathic pulmonary fibrosis (IPF), but there is no consensus as to which of these two agents should be regarded as first-line treatment. Objective: To provide real-world data on therapeutic decisions of pulmonary specialists, particularly the choice of the antifibrotic drug in patients with IPF. Methods: This was a multicenter, prospective survey collecting clinical data of patients with IPF considered as candidates for antifibrotic treatment between September 2019 and December 2020. Clinical characteristics and

APA, Harvard, Vancouver, ISO, and other styles

26

Roman, Jesse, and Hirofumi Chiba. "B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents." American Journal of Respiratory Cell and Molecular Biology 64, no. 6 (2021): 652–54. http://dx.doi.org/10.1165/rcmb.2021-0101ed.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Budenz, Donald L., Mark Pyfer, Kuldev Singh, Jeffrey Gordon, Jody Piltz-Seymour, and Edwin U. Keates. "Comparison of Phacotrabeculectomy With 5-Fluorouracil, Mitomycin-C, and Without Antifibrotic Agents." Ophthalmic Surgery, Lasers and Imaging Retina 30, no. 5 (1999): 367–74. http://dx.doi.org/10.3928/1542-8877-19990501-08.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Adtani, Pooja, Narasimhan Malathi, Kannan Ranganathan, Sivaswamy Lokeswari, and Alan Mathew Punnoose. "Antifibrotic effect of Ocimum basilicum L. and linalool on arecoline-induced fibrosis in human buccal fibroblasts." Translational Research in Oral Oncology 3 (January 1, 2018): 2057178X1876447. http://dx.doi.org/10.1177/2057178x18764471.

Full text

Abstract:

Aim: To explore Ocimum basilicum L. (sweet basil) and linalool for their antifibrotic activity in an arecoline-induced in vitro fibrotic model. Methods: Leaf extract of O. basilicum L. (LEOB) and linalool were used as experimental agents to test their antifibrogenic activity in vitro. Half-maximal inhibitory concentration (IC50) for arecoline, ethanolic LEOB, and linalool was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. To evaluate the antifibrotic effect of ethanolic LEOB and linalool on pretreatment, that is, both the testing agents were adde

APA, Harvard, Vancouver, ISO, and other styles

29

Lv, Wenshan, Fan Fan, Yangang Wang, et al. "Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD." Physiological Genomics 50, no. 1 (2018): 20–34. http://dx.doi.org/10.1152/physiolgenomics.00039.2017.

Full text

Abstract:

Chronic kidney disease (CKD), defined as reduced glomerular filtration rate, is increasingly becoming a major public health issue. At the histological level, renal fibrosis is the final common pathway leading to end-stage renal disease, irrespective of the initial injury. According to this view, antifibrotic agents should slow or halt the progression of CKD. However, due to multiple overlapping pathways stimulating fibrosis, it has been difficult to develop antifibrotic drugs that delay or reverse the progression of CKD. MicroRNAs (miRNAs) are small noncoding RNA molecules, 18–22 nucleotides i

APA, Harvard, Vancouver, ISO, and other styles

30

Skurikhin, Evgenii, Vladimir Nebolsin, Darius Widera, et al. "Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis." International Journal of Molecular Sciences 21, no. 21 (2020): 8380. http://dx.doi.org/10.3390/ijms21218380.

Full text

Abstract:

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease characterized by interstitial fibrosis and progressive respiratory failure. Pirfenidone and nintedanib slow down but do not stop the progression of IPF. Thus, new compounds with high antifibrotic activity and simultaneously regenerative activity are an unmet clinical need. Recently, we showed that Treamid can help restoring the pancreas and testicular tissue in mice with metabolic disorders. We hypothesized that Treamid may be effective in antifibrotic therapy and regeneration of damaged lung tissue in pulmonary fibrosis. In

APA, Harvard, Vancouver, ISO, and other styles

31

Burgess, Heather A., Louis Eugene Daugherty, Thomas H. Thatcher та ін. "PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis". American Journal of Physiology-Lung Cellular and Molecular Physiology 288, № 6 (2005): L1146—L1153. http://dx.doi.org/10.1152/ajplung.00383.2004.

Full text

Abstract:

Pulmonary fibrosis is a progressive life-threatening disease for which no effective therapy exists. Myofibroblasts are one of the key effector cells in pulmonary fibrosis and are the primary source of extracellular matrix production. Drugs that inhibit the differentiation of fibroblasts to myofibroblasts have potential as antifibrotic therapies. Peroxisome proliferator-activated receptor (PPAR)-γ is a transcription factor that upon ligation with PPARγ agonists activates target genes containing PPAR response elements. PPARγ agonists have anti-inflammatory activities and may have potential as an

APA, Harvard, Vancouver, ISO, and other styles

32

Kumai, Yoshihiko. "Pathophysiology of Fibrosis in the Vocal Fold: Current Research, Future Treatment Strategies, and Obstacles to Restoring Vocal Fold Pliability." International Journal of Molecular Sciences 20, no. 10 (2019): 2551. http://dx.doi.org/10.3390/ijms20102551.

Full text

Abstract:

Communication by voice depends on symmetrical vibrations within the vocal folds (VFs) and is indispensable for various occupations. VF scarring is one of the main reasons for permanent dysphonia and results from injury to the unique layered structure of the VFs. The increased collagen and decreased hyaluronic acid within VF scars lead to a loss of pliability of the VFs and significantly decreases their capacity to vibrate. As there is currently no definitive treatment for VF scarring, regenerative medicine and tissue engineering have become increasingly important research areas within otolaryn

APA, Harvard, Vancouver, ISO, and other styles

33

Collins, Bridget F., and Ganesh Raghu. "Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis." European Respiratory Review 28, no. 153 (2019): 190022. http://dx.doi.org/10.1183/16000617.0022-2019.

Full text

Abstract:

Two antifibrotic medications (nintedanib and pirfenidone) were recommended (conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the 2015 IPF evidence-based guidelines. These medications have been shown to reduce the rate of decline in forced vital capacity among patients with IPF over time and are the only two disease-modulating pharmacological agents approved by regulatory agencies and available for clinical use worldwide. With the evolved standard of care for interstitial lung disease evaluation including routine use of high-resolution computed tomography

APA, Harvard, Vancouver, ISO, and other styles

34

Morrow, Lee E., Daniel Hilleman, and Mark A. Malesker. "Management of patients with fibrosing interstitial lung diseases." American Journal of Health-System Pharmacy 79, no. 3 (2021): 129–39. http://dx.doi.org/10.1093/ajhp/zxab375.

Full text

Abstract:

Abstract Purpose This article summarizes the appropriate use and pharmacology of treatments for fibrosing interstitial lung diseases, with a specific focus on the antifibrotic agents nintedanib and pirfenidone. Summary The interstitial lung diseases are a heterogenous group of parenchymal lung disorders with a common feature—infiltration of the interstitial space with derangement of the normal capillary-alveolar anatomy. Diseases characterized by fibrosis of the interstitial space are referred to as the fibrosing interstitial lung diseases and often show progression over time: idiopathic pulmo

APA, Harvard, Vancouver, ISO, and other styles

35

Zakaria, Sherin, та Alaa E. El-Sisi. "Daclatasvir and Sofosbuvir Mitigate Hepatic Fibrosis Through Downregulation of TNF-α / NF-κB Signaling Pathway". Current Molecular Pharmacology 13, № 4 (2020): 318–27. http://dx.doi.org/10.2174/1874467213666200116114919.

Full text

Abstract:

Background: Hepatic fibrosis is the major issue in chronic liver diseases such as chronic hepatitis C virus (HCV). The newly approved direct acting antiviral (DAA) agents such as Sofosbuvir (SOF) and daclatasvir (DAC) have been found to be associated with decreased fibrotic markers in HCV patients. Aim: This study tried to explore whether the reported antifibrotic effect of these drugs is antiviral dependent or drug induced. Method: Hepatic fibrosis was induced by (0.5ml/kg) CCl4 IP twice a week for six weeks. SOF (20 mg/kg/d) and DAC (30 mg/kg/d) were added in the last four weeks of treatment

APA, Harvard, Vancouver, ISO, and other styles

36

Yang, Cheng-Chun, Chin-Yu Chen, Yu-Ting Kuo, et al. "Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study." Diagnostics 12, no. 4 (2022): 1002. http://dx.doi.org/10.3390/diagnostics12041002.

Full text

Abstract:

Antifibrotic therapy has changed the treatment paradigm for idiopathic pulmonary fibrosis (IPF); however, a subset of patients still experienced rapid disease progression despite treatment. This study aimed to determine whether CT-based radiomic features can predict therapeutic response to antifibrotic agents. In this retrospective study, 35 patients with IPF on antifibrotic treatment enrolled from two centers were divided into training (n = 26) and external validation (n = 9) sets. Clinical and pulmonary function data were collected. The patients were categorized into stable disease (SD) and

APA, Harvard, Vancouver, ISO, and other styles

37

Duval, Florent, Jorge E. Moreno-Cuevas, Maria Teresa González-Garza, Carlos Rodríguez-Montalvo, and Delia Elva Cruz-Vega. "Liver Fibrosis and Protection Mechanisms Action of Medicinal Plants Targeting Apoptosis of Hepatocytes and Hepatic Stellate Cells." Advances in Pharmacological Sciences 2014 (2014): 1–11. http://dx.doi.org/10.1155/2014/373295.

Full text

Abstract:

Following chronic liver injury, hepatocytes undergo apoptosis leading to activation of hepatic stellate cells (HSC). Consequently, activated HSC proliferate and produce excessive extracellular matrix, responsible for the scar formation. The pandemic trend of obesity, combined with the high incidence of alcohol intake and viral hepatitis infections, highlights the urgent need to find accessible antifibrotic therapies. Treatment strategies should take into account the versatility of its pathogenesis and act on all the cell lines involved to reduce liver fibrosis. Medicinal plants are achieving p

APA, Harvard, Vancouver, ISO, and other styles

38

Duval, Florent, Jorge E. Moreno-Cuevas, María Teresa González-Garza, Carmen Maldonado-Bernal, and Delia Elva Cruz-Vega. "Liver Fibrosis and Mechanisms of the Protective Action of Medicinal Plants Targeting Inflammation and the Immune Response." International Journal of Inflammation 2015 (2015): 1–14. http://dx.doi.org/10.1155/2015/943497.

Full text

Abstract:

Inflammation is a central feature of liver fibrosis as suggested by its role in the activation of hepatic stellate cells leading to extracellular matrix deposition. During liver injury, inflammatory cells are recruited in the injurious site through chemokines attraction. Thus, inflammation could be a target to reduce liver fibrosis. The pandemic trend of obesity, combined with the high incidence of alcohol intake and viral hepatitis infections, highlights the urgent need to find accessible antifibrotic therapies. Medicinal plants are achieving popularity as antifibrotic agents, supported by th

APA, Harvard, Vancouver, ISO, and other styles

39

Knobloch, K., A. Gohritz, M. Spies, and P. M. Vogt. "ACE inhibitors as antifibrotic agents in atrial fibrillation: potential relevance in cardiac surgery." Interactive CardioVascular and Thoracic Surgery 7, no. 3 (2008): 475–76. http://dx.doi.org/10.1510/icvts.2007.174698a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Raja, S. G. "ACE inhibitors as antifibrotic agents in atrial fibrillation: potential relevance in cardiac surgery." Interactive CardioVascular and Thoracic Surgery 7, no. 3 (2008): 476. http://dx.doi.org/10.1510/icvts.2007.174698a1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Cassone, Giulia, Andreina Manfredi, Caterina Vacchi, et al. "Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows." Journal of Clinical Medicine 9, no. 4 (2020): 1082. http://dx.doi.org/10.3390/jcm9041082.

Full text

Abstract:

Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5–1% of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary complication of RA and it is responsible for 10–20% of mortality, with a mean survival of 5–8 years. However, nowadays there are no therapeutic recommendations for the treatment of RA-ILD. Therapeutic options for RA-ILD are complicated by the possible pulmonary toxicity of many disease modifying anti-rheumatic drugs (DMARDs) and by their unclear efficacy on pulmonary disease. Therefore, joint and lung involvement should be

APA, Harvard, Vancouver, ISO, and other styles

42

Hewitson, Tim D. "Renal tubulointerstitial fibrosis: common but never simple." American Journal of Physiology-Renal Physiology 296, no. 6 (2009): F1239—F1244. http://dx.doi.org/10.1152/ajprenal.90521.2008.

Full text

Abstract:

Regardless of etiology, all patients with chronic renal disease show a progressive decline in renal function with time. Fibrosis, so-called scarring, is a key cause of this pathophysiology. Fibrosis involves an excess accumulation of extracellular matrix (primarily composed of collagen) and usually results in loss of function when normal tissue is replaced with scar tissue. While recent major advances have led to a much better understanding of this process, many problems remain. We for instance know little about why some wounds heal and others scar and little about how many putative antifibrot

APA, Harvard, Vancouver, ISO, and other styles

43

Turan, Onur, and Bünyamin Sertoğullarından. "Efficacy and tolerability of antifibrotic agents in idiopathic pulmonary fibrosis: An experience from Turkey." Eurasian Journal of Pulmonology 23, no. 1 (2021): 59. http://dx.doi.org/10.4103/ejop.ejop_74_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Schnabl, Bernd, David Scholten, and David A. Brenner. "What is the potential role of antifibrotic agents for the treatment of liver disease?" Nature Clinical Practice Gastroenterology & Hepatology 5, no. 9 (2008): 496–97. http://dx.doi.org/10.1038/ncpgasthep1200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Liu, Xiaoqiu, Rennolds S. Ostrom, and Paul A. Insel. "cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts." American Journal of Physiology-Cell Physiology 286, no. 5 (2004): C1089—C1099. http://dx.doi.org/10.1152/ajpcell.00461.2003.

Full text

Abstract:

Pulmonary fibroblasts are recruited to sites of lung injury, where they are activated to produce extracellular matrix proteins and to facilitate repair. However, these cells become dysregulated in pulmonary fibrosis, producing excess collagen at sites of injury and forming fibrotic loci that impair lung function. In this study, we used WI-38 human lung fibroblasts and evaluated the ability of G protein-coupled receptor agonists to increase cAMP production and regulate cell proliferation and collagen synthesis. WI-38 cells increase cAMP in response to the β-adrenergic agonist isoproterenol (Iso

APA, Harvard, Vancouver, ISO, and other styles

46

SOLOMON, ABRAHAM, URIEL TICHO, and JOSEPH FRUCHT-PERY. "Late-Onset, Bleb-Associated Endophthalmitis following Glaucoma Filtering Surgery with or without Antifibrotic Agents." Journal of Ocular Pharmacology and Therapeutics 15, no. 4 (1999): 283–93. http://dx.doi.org/10.1089/jop.1999.15.283.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Lee, Y. S., K. Y. Kim, B. S. Yu, et al. "Development of hepatic fibrosis (cirrhosis) model in rats and screening of the antifibrotic agents." Toxicology Letters 95 (July 1998): 165. http://dx.doi.org/10.1016/s0378-4274(98)80660-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Law, Simon K. "A Modified Technique of Ahmed Glaucoma Valve Implantation with Adjunctive Use of Antifibrotic Agents." American Journal of Ophthalmology 146, no. 2 (2008): 156–58. http://dx.doi.org/10.1016/j.ajo.2008.05.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Baxter, Ruth M., Thomas P. Crowell, Margaret E. McCrann, Erica M. Frew, and Humphrey Gardner. "Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agents." Laboratory Investigation 85, no. 10 (2005): 1199–209. http://dx.doi.org/10.1038/labinvest.3700331.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Taufiq, Ahmad, Rosy Eko Saputro, Hendra Susanto, et al. "Synthesis of Fe3O4/Ag nanohybrid ferrofluids and their applications as antimicrobial and antifibrotic agents." Heliyon 6, no. 12 (2020): e05813. http://dx.doi.org/10.1016/j.heliyon.2020.e05813.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!